Nektar Therapeutics disclosed positive maintenance results from the 52‑week Phase IIb REZOLVE‑AD trial of rezpegaldesleukin (rezpeg) in moderate‑to‑severe atopic dermatitis. The trial showed high rates of EASI‑75 and EASI‑90 responses during the 36‑week blinded maintenance period across monthly and quarterly dosing arms, and meaningful itch reduction in responders, the company reported. Management announced plans for a Phase III program later this year and quickly completed a $460 million underwritten public offering to fund development. Nektar also disclosed an FDA agreement on induction and maintenance dosing for the Phase III design, reflecting regulatory alignment on a pathway forward. Rezpeg is an IL‑2 receptor‑targeting agent designed to expand regulatory T cells (Tregs). The data position rezpeg as a competitive late‑stage contender in inflammatory skin disease if confirmatory trials replicate durability and safety.